CN Patent

CN121154828A — 使用b-raf抑制剂和免疫检查点抑制剂治疗癌症的方法

Assigned to F Hoffmann La Roche AG · Expires 2025-12-19 · 0y expired

What this patent protects

本发明涉及在有和/或无MEK抑制剂的情况下组合使用B‑RAF和免疫检查点抑制剂治疗癌症的疗法，包括剂量方案。

USPTO Abstract

本发明涉及在有和/或无MEK抑制剂的情况下组合使用B‑RAF和免疫检查点抑制剂治疗癌症的疗法，包括剂量方案。

Drugs covered by this patent

cobimetinib-fumarate (COBIMETINIB FUMARATE)

Patent Metadata

Patent number: CN121154828A
Jurisdiction: CN
Classification: —
Expires: 2025-12-19
Drug substance claim: No
Drug product claim: No
Assignee: F Hoffmann La Roche AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.